阿比特龙在治疗前列腺癌方面的新进展  

Clinical progress of abiraterone in the treatment of metastatic prostatic cancer

作　　者：任桐[1] 林锦彬 刁勇[1] 

机构地区：[1]华侨大学生物医学学院,福建泉州612021 [2]厦门精艺兴业科技有限公司,福建厦门361004

出　　处：《中国生化药物杂志》2016年第7期205-208,212,共5页Chinese Journal of Biochemical Pharmaceutics

摘　　要：雄性激素阻断疗法可用于治疗中晚期及转移型前列腺癌,但36个月后最终会发展为去势抵抗型前列腺癌(castrationresistant prostate cancer,CRPC)。细胞色素P450酶CYP17是雄激素合成的必需因子,因此可作为CRPC治疗的新靶点,Ⅲ期临床试验结果表明,阿比特龙联合强的松可平均延长去势难治性前列腺癌患者生存期3.9个月。通过研究发现前列腺素受体靶线轴多靶点同时治疗,临床效果显著可作为一种前列腺癌治疗的新方法。Although androgen deprivation therapy can be used in the treatment of advanced and metastatic prostate cancer,but after an average of36 months,it will develop into castration resistant prostate cancer（CRPC）. The cytochrome P450 enzyme CYP17 is an essential step in androgen synthesis,so it could be a new critical therapeutic target in CRPC. In a phase III multicenter study,abiraterone in combination with prednisone improved median overall survival of men with CRPC by 3. 9 months. The study found that prostaglandin receptor target spool multiple targets for treatment at the same time,whose clinical effect is obvious and could be used as a new method for treatment of prostate cancer.

关 键 词：阿比特龙 前列腺癌 CYP17 

分 类 号：R697.3[医药卫生—泌尿科学]